XOMA Royalty Corp(XOMA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | 25.57 | EPS (ttm) | 1.57 | Insider Own | 0.29% | Shs Outstand | 17.7M | Perf Week | - |
| Market Cap | 0.71B | Forward P/E | - | EPS next Y | -106.1% | Insider Trans | - | Shs Float | 17.6M | Perf Month | -4.24% |
| Enterprise Value | 0.76B | PEG | - | EPS next Q | 0.18 | Inst Own | 42.16% | Short Float | 5.19% | Perf Quarter | 2.03% |
| Income | 0.02B | P/S | 14.63 | EPS this Y | -46.22% | Inst Trans | - | Short Ratio | 2.73 | Perf Half Y | 47.3% |
| Sales | 0.05B | P/B | 5.15 | EPS next 5Y | - | ROA | 10.55% | Short Interest | 0.91M | Perf YTD | 51.07% |
| Book/sh | 7.79 | P/C | 7.48 | EPS past 3/5Y | - 13.2% | ROE | 25.88% | 52W High | -11.17% ($45.22) | Perf Year | 48.01% |
| Cash/sh | 5.37 | P/FCF | 107.12 | Sales past 3/5Y | 105.3% 12.16% | ROIC | 11.55% | 52W Low | 80.22% ($22.29) | Perf 3Y | 135.74% |
| Dividend Est. | - | EV/EBITDA | 91.68 | EPS Y/Y TTM | 249.73% | Gross Margin | 93.16% | Volatility(W/M) | 3.85% 1.79% | Perf 5Y | 22.32% |
| Dividend TTM | - | EV/Sales | 15.65 | Sales Y/Y TTM | 13.16% | Oper. Margin | 10.25% | ATR (14) | 0.91 | Perf 10Y | 292.29% |
| Dividend Ex-Date | - | Quick Ratio | 3.59 | EPS Q/Q | 207.83% | Profit Margin | 41.08% | RSI (14) | 34.34 | Recom | 3 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.59 | Sales Q/Q | -22.59% | SMA20 | -5.68% ($42.59) | Beta | 0.88 | Target Price | $39 |
| Payout | - | Debt/Eq | 1.1 | Earnings | 2026/04/30 | SMA50 | -4.49% ($42.06) | Rel Volume | 0 | Prev Close | $40.17 |
| Employees | 14 | LT Debt/Eq | 0.96 | EPS/Sales Surpr. | 30.51% 0.26% | SMA200 | 19.2% ($33.7) | Avg Volume(3M) | 0.34M | Price | $40.17 |
| IPO | 1986/6/6 | Option/Short | Yes/No | Trades | 0 | Volume | - | Change | - |
💊 XOMA Royalty is a biotech royalty aggregator that builds its portfolio by acquiring the royalty economic rights of drug candidates. It diversifies its investments across more than 100 assets, ranging from early-stage partner programs to fully commercialized therapeutics, and operates as a US-listed company with a business model that secures royalty and milestone revenue from its external partners' sales without directly developing drugs itself.
Over the past 1 year, on the higher side
11% below its 1-year high.
Traded less than usual. That is 0% of its average volume.
XOMA makes money exceptionally well
Of every $100 in sales, $10.25 is kept as operating profit.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -46.2% this year.
Tap to view numbers
However, it looks expensive
Counting its debt, for $100 of yearly operating cash you would pay $9,168. Peers typically go for $2,000. Compared with its own 2-year average, it is 16% pricier now.
Tap to view numbers
Not enough quarters to judge yet
Only 1 quarter(s) reported, so no grade yet.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +22.3%. The S&P 500 did +65% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership looks stable
Institutions hold 42.2%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #182 of 598 in the industry
Based on market cap of $710M.
XOMA#182 XOMA Royalty Corp $710M PER 25.6 
WVE#182 Wave Life Sciences Inc $708M PER - 
ACHV#183 Achieve Life Sciences Inc $703M PER - 
SGMT#184 Sagimet Biosciences Inc $698M PER - 
ATTO#185 Attovia Therapeutics Inc $693M PER - 
FAQ
What kind of company is XOMA?
XOMA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of XOMA?
The market cap of XOMA is approximately $710M, ranking 2,896 within its sector.
What is the P/E ratio of XOMA?
XOMA has a P/E ratio of approximately 25.6x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for XOMA?
XOMA has recorded a 52-week high of $45.22 and a low of $22.29.
